Humoral response to two doses of BNT162b2 vaccination in people with HIV.

Authors :: Heftdal LD
Knudsen AD
Hamm SR
Hansen CB
Møller DL
Pries-Heje M
Fogh K
Hasselbalch RB
Jarlhelt I
Pérez-Alós L
Hilsted LM
Ostrowski SR
Gerstoft J
Grønbaek K
Bundgaard H
Iversen K
Garred P
Nielsen SD
Source :: Journal of internal medicine [J Intern Med] 2022 Apr; Vol. 291 (4), pp. 513-518. Date of Electronic Publication: 2021 Dec 16.
Publication Year :: 2022
Abstract: Background: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2.<br />Methods: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2.<br />Results: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%-97.0%], age- and sex-adjusted p = 0.027) of controls.<br />Conclusions: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.<br /> (© 2021 The Association for the Publication of the Journal of Internal Medicine.)